Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3370501 | Journal of Clinical Virology | 2008 | 4 Pages |
Abstract
Seven percent of patients had K65R mutations after failing an initial d4T/3TC/NVP regimen. Tenofovir, didanosine, and abcavir cannot be used in second-line regimen for these patients. HIV-1 RNA at the time that virological failure was detected correlated with the occurrence of K65R mutations.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Somnuek Sungkanuparph, Weerawat Manosuthi, Sasisopin Kiertiburanakul, Nipa Saekang, Wantanit Pairoj, Wasun Chantratita,